TY - JOUR
T1 - A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
AU - Bazarbashi, Shouki
AU - Su, Wen Pin
AU - Wong, Siew W.
AU - Singarachari, Ramanujam A.
AU - Rawal, Sudhir
AU - Volkova, Maria I.
AU - Bastos, Diogo A.
N1 - Funding Information:
This study and the Journal?s Rapid Service Fee was funded by AstraZeneca. We would like to thank BioQuest solutions for their editorial assistance. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors have contributed equally towards design, conception, review and finalization of manuscript. Shouki Bazarbashi has participated in speaker bureaus and advisory boards; and received conference support/research support from Lilly, Pfizer, Roche, Servier, Merck Serono, Janssen, Merck-Sharp and Dohme, Astellas, Bristol-Myers Squibb, AstraZeneca, Amgen, Kyowa Kirin, and Bayer. Ramanujam Anugonda Singarachari has been part of Advisory Boards for AstraZeneca and received consulting fees from AstraZeneca. Diogo A. Bastos has received research funding from Janssen, Astellas, and Bayer; honoraria from Janssen, Astellas, Bayer, AztraZeneca, BMS, MSD, and Roche; and has been consultant/advisor for Janssen, Astellas, Bayer, AztraZeneca, BMS, and MSD. All other authors confirm they do not have any conflict of interests. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.
AB - The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.
UR - http://www.scopus.com/inward/record.url?scp=85112008676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112008676&partnerID=8YFLogxK
U2 - 10.1007/s40487-021-00160-6
DO - 10.1007/s40487-021-00160-6
M3 - Review article
AN - SCOPUS:85112008676
VL - 9
SP - 311
EP - 327
JO - Oncology and Therapy
JF - Oncology and Therapy
SN - 2366-1070
IS - 2
ER -
